{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107278","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.501179+00:00","generated_at":"2026-05-17T14:53:27.469755+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AN2 Therapeutics Q2 net loss narrows to $6.5M; Chagas Phase 1 dosing underway; cash runway into 2028","bullets":["Net loss of $6.5M vs $14.4M in Q2 2024; R&D expenses down to $3.2M from $12.1M.","Cash, cash equivalents, and investments of $71.2M; operations funded into 2028.","Phase 1 FIH trial for Chagas drug AN2-502998 dosing started; Phase 2 planned for 2026.","Melioidosis observational study showed ~40% 90-day mortality; seeking U.S. government funding for Phase 2.","Two oncology development candidates (ENPP1 and PI3Kα) expected within 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107278","json":"https://secwatch.observer/filing/0000950170-25-107278.json","markdown":"https://secwatch.observer/filing/0000950170-25-107278.md","text":"https://secwatch.observer/filing/0000950170-25-107278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025107278/0000950170-25-107278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025107278/antx-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:53:27.469755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}